Skip to main content
Log in

Therapeutic equivalence of once- and thrice-daily glipizide

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Two cross-over studies were carried out in 23 patients with Type 2 diabetes, to examine whether glipizide, a potent sulphonylurea with fast and complete absorption and rapid elimination (t1/2<5 h), can be given once-daily without loss of therapeutic effect. In both studies, patients were randomly assigned to an initial dose of 7.5 mg once daily or 2.5 mg three-times daily, which was increased to 15 mg o.d. or 5 mg t.i.d. if the fasting plasma glucose remained over 10 mmol/l on the lower dosage. In Study 1 (n=11), administration once a day before breakfast was compared with intake before breakfast, lunch and early dinner (5 p.m.) and in Study 2 (n=12) the comparison was between intake once-daily before breakfast and dosing before breakfast, lunch, and at bedtime (10 p.m.).

Neither the 24-hour urinary glucose excretion nor HbA1, fasting plasma glucose, insulin or C-peptide levels differed between the once and three times daily administration with the third dose given before early dinner. The nadir plasma levels of glipizide were not significantly different and were often too low to be detected. Postponing the third dose until 10 p.m. did not produce any improvement in HbA1 or in fasting plasma glucose, insulin or C-peptide. The mean nadir glipizide levels following this schedule were twice as high as those after once-daily administration.

As expected, the plasma glipizide after breakfast was higher when the whole dose was taken before breakfast than when it was divided. The corresponding plasma level of insulin was higher and that of plasma glucose was lower. The after-lunch levels of glipizide did not differ significantly, and there was no after-lunch difference in plasma insulin or glucose.

It appears that the major effect of glipizide is to augment insulin availability following meals, whilst it has little influence on nocturnal glucose control. In a daily dose of 7.5 mg or more, glipizide can be taken once daily without loss of efficacy, at least in areas with Northern European meal schedules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Wåhlin-Boll E, Almér L-O, Melander A (1982) Bioavailability, kinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokinet 7: 363–372

    Google Scholar 

  2. Wåhlin-Boll E, Melander A, Sartor G, Scherstén B (1980) Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects. Eur J Clin Pharmacol 18: 279–283

    Google Scholar 

  3. Östman J, Christenson I, Jansson B, Weiner L (1981) The antidiabetic effect and pharmacokinetic properties of glipizide. Acta Med Scand 210: 173–180

    Google Scholar 

  4. Herbert V, Gottlieb CW, Bleicher SJ (1965) Coated charcoal immunoassay of insulin. J Clin Endocrinol 25: 1375–1384

    Google Scholar 

  5. Kuzuya T, Matsuda A, Saito T, Yoshida S (1976) Human C-peptide immunoreactivity (CRP) in blood and urine — evaluation of a radioimmunoassay method and its clinical applications. Diabetologia 12: 511–518

    Google Scholar 

  6. Wåhlin-Boll E, Melander A (1979) High-performance liquid chromatographic determination of glipizide and some other sulfonylurea drugs in serum. J Chromatogr 164: 541–546

    Google Scholar 

  7. Asplund K, Wiholm B-E, Lithner F (1983) Glibenclamide-associated hypoglycaemia: A report on 57 cases. Diabetologia 24: 412–417

    Google Scholar 

  8. Wåhlin-Boll E, Sartor G, Melander A, Scherstén B (1982) Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 22: 21–25

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wåhlin-Boll, E., Groop, L., Karhumaa, S. et al. Therapeutic equivalence of once- and thrice-daily glipizide. Eur J Clin Pharmacol 31, 95–99 (1986). https://doi.org/10.1007/BF00870994

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00870994

Key words

Navigation